top of page
CSTI-500 has the potential to provide a transformative therapy, not just for addressing hyperphagia in PWS, but also for tackling many of the associated psychiatric co-morbidities.


Triple Monoamine Reuptake Inhibitor for the treatment of hyperphagia in Prader-Willi Syndrome.

We believe that CSTI-200 is a potentially ideal GlyT1 inhibitor that can be used to treat debilitating LID. We are striving to provide this potentially breakthrough therapy to patients in need.


Advanced preclinical GlyT-1 inhibitor for the treatment of LID in Parkinson's disease.

CSTI-100 / HBS-102

MCHR1 antagonist for the treatment of rare neurological disorders.

bottom of page